Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma

Clinical and Experimental Dermatology

Volumn 29, Issue 5, 2004, Pages 518-525

  Vidal, D ^a   Matias Guiu X ^b   Alomar, A ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL ARNAU DE VILANOVA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; GRANZYME B; IMIQUIMOD; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53; PROTEIN S 100;

ADULT; AGED; APOPTOSIS; ARTICLE; BASAL CELL CARCINOMA; CANCER INFILTRATION; CANCER REGRESSION; CANCER SIZE; CAUCASIAN; CLINICAL TRIAL; CREAM; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; EROSION; ERYTHEMA; FEMALE; FOLLOW UP; HEADACHE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; INFLAMMATION; INFLAMMATORY INFILTRATE; LYMPHOCYTE; MACROPHAGE; MAJOR CLINICAL STUDY; MALAISE; MALE; NICK END LABELING; OPEN STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUSTULE; SIDE EFFECT; TREATMENT OUTCOME; TUMOR BIOPSY;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, BASAL CELL; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; SKIN NEOPLASMS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 4644228445     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2004.01601.x     Document Type: Article

References (19)

1. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002; 27: 571-7.
2. Wagner TL, Ahonen CL, Couture AM et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 1999; 191: 10-9.
3. Suzuki H, Wang B, Shivji Gm et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000; 114: 135-41.
4. Tomai MA, Imbertson LM, Stanczak TL et al. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol 2000; 203: 55-65.
5. Beutner KR, Geisse JK, Helman D et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41: 1002-7.
6. Marks R, Gebauer K, Shumack S et al. Imiquimod 5% cream in the treatment of superficial BCC. results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001; 44: 807-13.
7. Geisse JK, Rich P, Pandya A et al. Imiquimod 5% cream for the treatment of superficial BCC. a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002; 47: 390-8.
8. Shumack S, Robinson J, Kossard S et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular BCC. comparison of dosing regimens. Arch Dermatol 2002; 138: 1165-71.
9. Sterry W, Herrera E, Takwale A et al. Imiquimod 5% cream for the treatment of superficial and nodular BCC. randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002; 147: 1227-36.
10. Weedon D. Tumors of the epidermis. Basal cell carcinoma. In: Skin Pathology, 1st edn. London: Churchill Livingstone, Harcourt Publishers 1997, 647-51.
11. Tosteson AN, Weinstein MC, Wittenberg J et al. ROC curve regression analysis: The use of ordinal regression models for diagnostic test assessment. Environ Health Perspect 1994; 102: 73-81.
12. Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol 2002; 147: 41-7.
13. Rippey JJ. Why classify basal cell carcinomas? Histopathology 1998; 32: 393-8.
14. Ramdial PK, Madaree A, Reddy R et al. Bcl-2 protein expression in agressive and non-agressive basal cell carcinomas. J Cutan Pathol 2000; 27: 283-91.
15. Abdelsayed RA, Guijarro-Rojas M, IbrahImiq NA et al. Immunohistochemical evaluation of basal cell carcinoma and trichepithelioma using Bcl-2, Ki767, PCNA, and p53. J Cutan Pathol 2000; 27: 169-75.
16. Schon M, Bong AB, Drewniok C et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003; 95: 1138-49.
17. Wikonkal NM, Berg RJW et al. Bcl-2 vs p53 protein expression and apoptotic rate in human nonmelanoma skin cancers. Arch Dermatol 1997; 133: 599-602.
18. Barnetson R, Halliday G, Satchell A et al. Cell infiltrates in BCC tumors after treatment with imiquimod 5% cream. JEADV 2002; 16: 151.
19. Urosevic M, Maier T, Benninghoff B et al. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003; 139: 1325-32.